1. Stocks
  2. AstraZeneca Pharma India Ltd.
  3. Swot
swot-logo

AstraZeneca Pharma India Ltd. SWOT Analysis: Strengths, Weakness, Opportunity, and Threats

AstraZeneca Pharma India Ltd. has 17 Strengths, 7 Weaknesses, 3 Opportunities and 2 Threats. The SWOT product gives you a quick x-ray of a stock's outlook and potential

Add SWOT widget to your site/app

Companies with no Debt

Benjamin Graham Value Screen

30 Day SMA crossing over 200 Day SMA, and current price greater than open

Strong Momentum: Price above short, medium and long term moving averages

Consistent Highest Return Stocks over Five Years

Rising Net Cash Flow and Cash from Operating activity

Strong QoQ EPS Growth in recent results

Expensive Performers (DVM)

PEG lower than Industry PEG

High Momentum Scores (Technical Scores greater than 50)

Overbought by Money Flow Index (MFI)

Growth in Net Profit with increasing Profit Margin (QoQ)

Increasing Revenue every Quarter for the past 4 Quarters

Book Value per share Improving for last 2 years

Companies with Zero Promoter Pledge

Decrease in Provision in recent results

Top Gainers

PE higher than Industry PE

High PE (PE > 40)

Stocks with Expensive Valuations according to the Trendlyne Valuation Score

Red Flag: Resignation of Top Management

Increasing Trend in Non-Core Income

Sell Zone: Stocks in the sell zone based on days traded at current PE and P/BV

Stocks Underperforming their Industry Price Change in the Quarter

Mutual Funds Increased Shareholding in Past Month

Mutual Funds Increased Shareholding over the Past Two Months

Mf buying for 2 months

Companies with high market cap, lower public shareholding

MFs decreased their shareholding last quarter

Stocks in PE Buy Zone with Reasonable Durability Score, and Rising Momentum Score

Expensive Performers (DVM)

Average Bullish Trend - Stocks with Medium Trendlyne Momentum Score versus Benchmarks

Decline in Quarterly Net Profit with falling Profit Margin (YoY)